RU2011148918A - Иммуноглобулин с двумя вариабельными доменами и его применение - Google Patents

Иммуноглобулин с двумя вариабельными доменами и его применение Download PDF

Info

Publication number
RU2011148918A
RU2011148918A RU2011148918/10A RU2011148918A RU2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918/10 A RU2011148918/10 A RU 2011148918/10A RU 2011148918 A RU2011148918 A RU 2011148918A RU 2011148918 A RU2011148918 A RU 2011148918A
Authority
RU
Russia
Prior art keywords
antigen
fragment
parent antibody
specified
test sample
Prior art date
Application number
RU2011148918/10A
Other languages
English (en)
Russian (ru)
Inventor
Тарик ГХАЮР
Сьюзан Э. БРОУФИ
Сушил Г. ДЕВАРЕ
Фрэнк К. ГРЕНЬЕ
Джеффри А. МУР
Цяоцяо ЖУАНЬ
Сергей И. ТЕТИН
Дженнифер М. СТЕЙНХАУС
Цзюньцзян ЛЮ
Салман АЛИ
Хина Н. САИД
Original Assignee
Эбботт Лэборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз filed Critical Эбботт Лэборетриз
Publication of RU2011148918A publication Critical patent/RU2011148918A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011148918/10A 2009-05-01 2010-04-30 Иммуноглобулин с двумя вариабельными доменами и его применение RU2011148918A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17480009P 2009-05-01 2009-05-01
US61/174,800 2009-05-01
PCT/US2010/033246 WO2010127294A2 (en) 2009-05-01 2010-04-30 Dual variable domain immunoglobulins and uses thereof

Publications (1)

Publication Number Publication Date
RU2011148918A true RU2011148918A (ru) 2013-06-10

Family

ID=43032808

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011148918/10A RU2011148918A (ru) 2009-05-01 2010-04-30 Иммуноглобулин с двумя вариабельными доменами и его применение

Country Status (14)

Country Link
US (1) US20110008766A1 (enExample)
EP (1) EP2424566A4 (enExample)
JP (1) JP2012525441A (enExample)
KR (1) KR20140014382A (enExample)
CN (1) CN102458459A (enExample)
AU (1) AU2010242840B2 (enExample)
BR (1) BRPI1012195A2 (enExample)
CA (1) CA2760332A1 (enExample)
IL (1) IL216048A0 (enExample)
MX (1) MX2011011670A (enExample)
RU (1) RU2011148918A (enExample)
SG (1) SG175426A1 (enExample)
TW (1) TW201116624A (enExample)
WO (1) WO2010127294A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2126127B1 (en) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
KR20150080033A (ko) 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
US20140295497A1 (en) 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2014037811A2 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
GB201308271D0 (en) * 2013-05-08 2013-06-12 Nat Univ Ireland Semi-automated whole blood immuno potency assay
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9822172B2 (en) 2013-11-06 2017-11-21 Astute Medical, Inc. Assays for IGFBP7 having improved performance in biological samples
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
ES2571441B1 (es) * 2014-11-24 2017-03-07 Instituto De Investigación Sanitaria - Fundación Jiménez Díaz Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3684801A1 (en) * 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Multivalent mono- or bispecific recombinant antibodies for analytic purpose
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
WO2023278520A1 (en) * 2021-06-30 2023-01-05 Board Of Regents, The University Of Texas System Polypeptides targeting cd70-positive cancers
CN114366853B (zh) * 2022-01-20 2023-04-14 华东理工大学 一种高诱骨活性牙种植体涂层及其制备方法
CN119708212A (zh) * 2023-09-21 2025-03-28 东莞市朋志生物科技有限公司 检测hiv p24的抗体对、试剂和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP2340849A1 (en) * 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
BR0213078A (pt) * 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
MX2007011735A (es) * 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) * 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
AR061246A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
PL3339445T3 (pl) * 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009003142A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland, Stanford Junior University Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
ES2628395T3 (es) * 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
EP2235053A1 (en) * 2007-10-19 2010-10-06 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
BRPI0919426A2 (pt) * 2008-09-30 2015-12-15 Abbott Lab métodos melhorado de exposição de rna
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9120870B2 (en) * 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
UY34556A (es) * 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
WO2013101993A2 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl

Also Published As

Publication number Publication date
TW201116624A (en) 2011-05-16
CA2760332A1 (en) 2010-11-04
KR20140014382A (ko) 2014-02-06
IL216048A0 (en) 2012-01-31
WO2010127294A2 (en) 2010-11-04
AU2010242840A1 (en) 2011-12-15
WO2010127294A3 (en) 2011-01-20
EP2424566A4 (en) 2013-07-31
MX2011011670A (es) 2011-11-18
CN102458459A (zh) 2012-05-16
EP2424566A2 (en) 2012-03-07
SG175426A1 (en) 2011-12-29
AU2010242840B2 (en) 2014-04-17
BRPI1012195A2 (en) 2018-04-24
US20110008766A1 (en) 2011-01-13
JP2012525441A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
JP7346300B2 (ja) 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
JP2022115986A5 (enExample)
JP2021505844A (ja) Ｇｆａｐとｕｃｈ−ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
JP2021505843A (ja) グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
JP2020521951A (ja) 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
RU2011121818A (ru) Способ иммунологического анализа белка cxcl1 человека
JP2020516603A5 (enExample)
US20240392034A1 (en) Clinical assessment of m-protein response in multiple myeloma
JP2023514952A (ja) 抗ｄ－ダイマー組換え抗体、その方法及び使用
CA3180569A1 (en) Neutralizing antibody assay for therapeutic proteins
RU2016106708A (ru) Лекарственное средство, содержащее антитело к фосфолипазе d4
WO2020069303A1 (en) Antibodies against soluble bcma
US20190317086A1 (en) SPR-based dual-binding assay for the functional analysis of multispecific molecules
JP7416485B2 (ja) スイッチング結合剤、その製造方法、及びそれを用いた薬学組成物、検査キット及び抗原と抗体との分析方法
KR102601835B1 (ko) 말 인플루엔자 바이러스 h3n8형에 특이적인 단일클론항체 및 이를 이용한 말인플루엔자 바이러스 검출용 조성물
CN118078986A (zh) 一种抗Nectin-4单克隆抗体药物或其衍生物的特异性结合剂及其应用
TWI741216B (zh) 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途
JP5770092B2 (ja) ヒトｈｉｇ１ポリペプチドに対するモノクローナル抗体
TW202216758A (zh) 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組
WO2020264410A1 (en) Troponin t binding agents and uses thereof
CN114853887B (zh) 一种特异性结合α-突触核蛋白的抗体及其应用
US20210278403A1 (en) Lateral flow assay for assessing recombinant protein expression or reporter gene expression
JP7366411B2 (ja) ヒトαディフェンシンＨＤ５を検出する方法及びキット、並びにこれらにおいて用いられる抗体
US20230242636A1 (en) Monoclonal antibodies targeted to human taxilin alpha and methods for use of same

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150202